ALKBH5 thus contributes to EOC cisplatin resistance via activation of the JAK2/STAT3 signaling pathway.[112] FTO‐mediated m6A reduction and doxorubicin resistance via STAT3 activation also occur in breast cancer.[58] In contrast, in pancreatic ductal adenocarcinoma (PDAC), ALKBH5 is downregulated and is associated with gemcitabine resistance. Here, ALKBH5 is linked to pancreatic ductal adenocarcinoma.